


WHAT IS CLAIMED IS:

1. A compound of the following formula A-3:



5

wherein,

R<sub>1</sub> is haloalkyl, hydroxyalkyl, haloalkenyl, heterocycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenylamino, unsubstituted benzyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxylalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl.

*sub A*

10

2. A compound according to claim 1 which is in the form of a pharmaceutically acceptable salt thereof.

15

3. A compound according to claim 2 wherein said pharmaceutically acceptable salt is hydrochloride salt.


*sub B*

4. A compound according to claim 1 which is in the form of a prodrug thereof.

5. A compound according to claim 1 which is in the form of a liposome delivery system.

6. A compound according to claim 6 wherein R<sub>1</sub> is alkyl or substituted or unsubstituted phenyl.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the following formula A-3:



5

wherein,

10

R<sub>1</sub> is alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenylamino, substituted or unsubstituted benzyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxylalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl;

and, a pharmaceutically acceptable carrier.

15

8. A pharmaceutical composition according to claim 7 which is in the form of a pharmaceutically acceptable salt thereof.

20

9. A pharmaceutical composition according to claim 8 wherein said pharmaceutically acceptable salt is selected from the group consisting of chloride, bromide, sulfate, nitrate, phosphate, sulfonate, formate, tartrate, maleate, malate, citrate, benzoate, salicylate, ascorbate, and mixtures thereof.

10. A pharmaceutical composition according to claim 8 wherein said pharmaceutically acceptable salt is hydrochloride salt.

25

11. A pharmaceutical composition according to claim 7 which is in the form of a prodrug thereof.

12. A pharmaceutical composition according to claim 7 which is in the form of a liposome delivery system.


13. A pharmaceutical composition according to claim 7 wherein said compound is micronized and said composition is suitable for administration by injection.

5 14. A pharmaceutical composition according to Claim 7 wherein said compound is coupled to a soluble polymer.

15. A pharmaceutical composition according to Claim 7 wherein said compound is coupled to a biodegradable polymer.

10 16. A pharmaceutical composition according to Claim 7 wherein R<sub>1</sub> is alkyl or substituted or unsubstituted phenyl.

15 17. A pharmaceutical composition comprising a therapeutically enhanced amount of a compound of the following formula A-3:




A-3

wherein,

20 R<sub>1</sub> is alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenylamino, substituted or unsubstituted benzyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl; a therapeutically effective amount of a chemotherapeutic agent; and, a pharmaceutically acceptable carrier.

25 18. A pharmaceutical composition according to claim 17 which further comprises a therapeutically effective amount of a potentiator.

19. A unit dosage form comprising a compound of the following formula A-3:



5

wherein,

R<sub>1</sub> is alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenylamino, substituted or unsubstituted benzyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl;  
and, a pharmaceutically acceptable carrier.

20. A unit dosage form according to claim 19 which comprises from 1 mg to 1000 mg of said compound.

21. A unit dosage form according to claim 19 which is in the form of a liposome delivery system.


20 22. A unit dosage form according to claim 19 wherein said compound is micronized and said carrier is suitable for administration by injection.

23. A unit dosage form according to claim 19 wherein said compound is coupled to a soluble polymer.

25 24. A unit dosage form according to claim 19 wherein said compound is coupled to a biodegradable polymer.

25.

A pharmaceutical kit comprising:  
a therapeutically effective amount of a compound of the following formula A-3:



A-3

5

wherein,

10

R<sub>1</sub> is alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenylamino, substituted or unsubstituted benzyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxylalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl;  
and, instruction for use in treating cancer or a viral infection.

100 90 80 70 60 50 40 30 20 10